Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent News

Oct 30, 2017
London, UK and Carlsbad, CA, 30 Oct 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.
Sep 05, 2017
- Morgan Stanley 15th Annual Healthcare Conference on 13 September – - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September-
Aug 07, 2017
- Epidiolex® NDA submission process underway – - Conference call today at 4:30 p.m. EST -

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Submit
Epidiolex
Lennox-Gastaut Syndrome
Submit
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (Partnered)

Sativex
Ms Spasticity
Approved